Multiple Sclerosis Clinical Trials

Testing BMS-986368 against a placebo for multiple sclerosis spasticity

Explore this study →

There are 4 groups in this study. Groups A, B and C receive BMS-986368. Group D, the placebo group, receives Placebo.

Sites in Edmonton, Lévis and 4 more cities

Official title: A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity

Multiple Sclerosis Spasticity · Celgene

Comparing 4 approaches for relapsing multiple sclerosis

Explore this study →

There are 4 groups in this study. Groups A, C and D receive Remibrutinib oral treatment. Group B, the comparison group, receives Ocrelizumab.

Sites in Edmonton, Lévis and 2 more cities

Official title: Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

Relapsing Multiple Sclerosis · Novartis Pharmaceuticals

Testing Repetitive Transcranial Magnetic against a placebo for multiple sclerosis

Explore this study →

There are 2 groups in this study. Group A, the comparison group, receives Repetitive Transcranial Magnetic Stimulation. Group B, the sham group, receives Repetitive Transcranial Magnetic Stimulation.

One site, in Gatineau

Official title: Repetitive Transcranial Magnetic Stimulation (rTMS) in MS Induced Spastic Paraparesis

Multiple Sclerosis · Clinique Neuro-Outaouais

Testing Remibrutinib (blinded) with Remibrutinib (Open label) against a placebo for secondary progressive multiple sclerosis (SPMS)

Explore this study →

There are 2 groups in this study. Group A receives one or more of: Remibrutinib (blinded) and Remibrutinib (Open label). Group B, the placebo group, receives Placebo, together with one or more of: Remibrutinib (Open label).

Sites in Montreal, Burnaby and 8 more cities

Official title: A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

Secondary Progressive Multiple Sclerosis (SPMS) · Novartis Pharmaceuticals

Comparing THC with CBD for multiple sclerosis

Explore this study →

There are 2 groups in this study. Group A receives THC. Group B receives CBD.

2 sites in Calgary

Official title: Cannabis (THC vs. CBD) in Multiple Sclerosis

Multiple Sclerosis · University of Calgary

Comparing Integrated Dual-task EMG Biofeedback with Traditional Balance Exercise Training for multiple sclerosis

Explore this study →

There are 2 groups in this study. Group A receives Integrated Dual-task EMG Biofeedback Training (EMG-BF). Group B, the comparison group, receives Traditional Balance Exercise Training (BAL-EX).

One site, in Hamilton

Official title: EMG Biofeedback Training to Improve Balance in Individuals with Multiple Sclerosis

Multiple Sclerosis · McMaster University

Testing Balance training with FES against a placebo for multiple sclerosis

Explore this study →

There are 3 groups in this study. Group A, the sham group, receives Balance training only. Group B, the comparison group, receives Balance training with FES. Group C, the comparison group, receives Balance training wiith combined neuromodulation (TSCS+FES).

One site, in Toronto

Official title: Innovative Approaches to Enhance Balance and Neuroplasticity in Multiple Sclerosis

Multiple Sclerosis · University Health Network, Toronto

Comparing 3 approaches for multiple sclerosis (MS)

Explore this study →

There are 3 groups in this study. Groups A, B and C receive one or more of: Metformin and Placebo.

One site, in Toronto

Official title: A Phase I Double Blind Study of Metformin Acting on Endogenous Neural Progenitor Cells in Children and Young Adults With Multiple Sclerosis

Multiple Sclerosis (MS) · The Hospital for Sick Children

Comparing 4 approaches for multiple sclerosis

Explore this study →

There are 4 groups in this study. Group A receives RO7121932 IV. Groups B and C receive RO7121932 SC. Group D receives one or more of: RO7121932 IV and RO7121932 SC.

One site, in Montreal

Official title: A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis

Multiple Sclerosis · Hoffmann-La Roche

Comparing AZD0120 - Regimen 1 with AZD0120 - Regimen 2 for multiple sclerosis

Explore this study →

There are 2 groups in this study. Groups A and B receive one or more of: AZD0120 - Regimen 1 and AZD0120 - Regimen 2.

One site, in Montreal

Official title: An Open-label Study of AZD0120 in Adults With Multiple Sclerosis

Multiple Sclerosis · AstraZeneca

Testing ETNATM-ProgMS for relapsing remitting multiple sclerosis (RRMS)

Explore this study →

Everyone in this study is in one group and receives ETNATM-ProgMS.

Sites in Montreal, Calgary and 8 more cities

Official title: ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS

Relapsing Remitting Multiple Sclerosis (RRMS) · Novartis Pharmaceuticals

Cannabis as a Complementary Treatment in Multiple Sclerosis

Explore this study →

There are 4 groups in this study. Groups A, B and C receive Cannabis oil vs placebo. Group D, the placebo group, receives Cannabis oil vs placebo.

One site, in Montreal

Multiple Sclerosis · Centre hospitalier de l'Université de Montréal (CHUM)